Indegene Limited, a digital-first life sciences commercialization company, has announced the opening of a new center in Pune, marking a significant expansion of its operations in India. This strategic move aims to leverage Pune's rich pool of skilled technology, management, and medical talent to enhance the company's capabilities in serving its global clientele.

Expanding Capabilities and Reach

The new center in Pune is expected to bolster Indegene's ability to help clients accelerate innovation and scale global operations. This expansion comes as part of the company's ongoing efforts to strengthen its position in the life sciences commercialization sector.

Strategic Location and Talent Pool

Pune, known for its thriving technology and healthcare ecosystem, offers Indegene access to a highly skilled workforce. This talent pool is crucial for the company's mission to deliver improved healthcare outcomes for patients worldwide through its digital-first approach.

Global Presence and Client Base

Indegene serves a prestigious client base that includes:

• The world's top 20 biopharma companies
• Emerging biotech firms
• Medical device companies

With approximately 5,000 employees worldwide, Indegene operates across:

• 9 operations hubs
• 20 offices spanning North America, Europe, and Asia

Company Overview

Indegene Limited combines deep healthcare expertise with a digital-first approach to assist pharmaceutical, biotech, and medical device companies in commercializing their products. The company's services encompass:

• Product development support
• Market entry strategies
• Global operations scaling
• Lifecycle management

Future-Ready Healthcare Solutions

As a digital-first company, Indegene aims to provide personalized, scalable, and omnichannel experiences for patients and physicians. This approach is designed to make healthcare organizations future-ready, enabling them to navigate the rapidly evolving landscape of life sciences and healthcare delivery.

The expansion in Pune underscores Indegene's commitment to growth and innovation in the life sciences sector, positioning the company to better serve its global clients and contribute to advancing healthcare solutions worldwide.

Indegene Limited has announced that its shareholders have approved a special resolution for the variation in utilization of Initial Public Offering (IPO) proceeds. The decision was made through a remote e-voting postal ballot that concluded on August 12, 2025.

Voting Results

The voting results revealed strong support for the resolution:

The total votes polled represented 38.53% of the company's outstanding shares, with 92,487,493 votes cast. An overwhelming 99.99% of the votes were in favor of the resolution, while only 0.01% were against it.

Shareholder Participation

Out of 154,043 equity shareholders eligible to vote as of the July 4, 2025 cut-off date:

• 718 members voted in favor of the resolution
• 82 members voted against it

E-Voting Process

The e-voting period ran from July 14 to August 12, 2025, allowing shareholders to cast their votes electronically. The process was conducted in compliance with the Companies Act, 2013, and SEBI regulations.

Scrutinizer's Report

Madhwesh K, a Practicing Company Secretary from Bengaluru, acted as the Scrutinizer for the postal ballot process. The Scrutinizer's report, dated August 13, 2025, confirmed the validity of the voting process and results.

Transparency and Disclosure

In line with regulatory requirements, Indegene Limited has made the voting results and Scrutinizer's report available on the company's website ( www.indegene.com ) and the National Securities Depository Limited's website ( www.evoting.nsdl.com ).

The approval of this resolution allows Indegene Limited to modify the utilization of its IPO proceeds, potentially enabling the company to adapt its financial strategies to current market conditions or business needs. Shareholders' strong support for this decision indicates confidence in the management's plans for fund allocation.

Indegene Limited, headquartered in Bengaluru, continues to maintain transparency with its investors through timely disclosures and adherence to regulatory requirements.